209 related articles for article (PubMed ID: 25804480)
1. New immunotherapeutic strategies for the treatment of neuroblastoma.
Croce M; Corrias MV; Rigo V; Ferrini S
Immunotherapy; 2015; 7(3):285-300. PubMed ID: 25804480
[TBL] [Abstract][Full Text] [Related]
2. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
[TBL] [Abstract][Full Text] [Related]
3. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
[TBL] [Abstract][Full Text] [Related]
4. Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
Talleur AC; Triplett BM; Federico S; Mamcarz E; Janssen W; Wu J; Shook D; Leung W; Furman WL
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1910-1917. PubMed ID: 28733263
[TBL] [Abstract][Full Text] [Related]
5. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.
Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2001 Nov; 19(22):4189-94. PubMed ID: 11709561
[TBL] [Abstract][Full Text] [Related]
7. Anti-GD2 immunotherapy for neuroblastoma.
Sait S; Modak S
Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of human neuroblastoma.
Prigione I; Corrias MV; Airoldi I; Raffaghello L; Morandi F; Bocca P; Cocco C; Ferrone S; Pistoia V
Ann N Y Acad Sci; 2004 Dec; 1028():69-80. PubMed ID: 15650233
[TBL] [Abstract][Full Text] [Related]
10. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.
Cheung IY; Hsu K; Cheung NK
J Clin Oncol; 2012 Feb; 30(4):426-32. PubMed ID: 22203761
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.
Szychot E; Peregud-Pogorzelski J; Wawryków P; Brodkiewicz A
Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):1001-1004. PubMed ID: 27708204
[TBL] [Abstract][Full Text] [Related]
12. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
McGinty L; Kolesar J
Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
[TBL] [Abstract][Full Text] [Related]
13. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
14. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
[TBL] [Abstract][Full Text] [Related]
15. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Mora J
Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
[TBL] [Abstract][Full Text] [Related]
16. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
18. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
19. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
Med Pediatr Oncol; 2003 Dec; 41(6):508-15. PubMed ID: 14595707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]